Abstract
Purpose: This study was performed to evaluate whether a lower dose (0.2 mg) of cetrorelix would prevent premature LH surge in patients undergoing controlled ovarian hyperstimulation. Methods: Controlled ovarian hyperstimulation was carried out in 45 patients, starting on menstrual cycle day 3 with recombinant FSH (r-FSH), and a cetrorelix of 0.2 mg was administered from day 5 evening of ovarian stimulation until the day before hCG injection. Results: There was a statistically significant decrease in serum LH level one day after the first cetrorelix injection and on the day of hCG administration. Serum LH concentrations were maintained constantly low during the follicular phase with no premature LH surge occurring in any of the patients. Clinical pregnancy was achieved for 18 women (40%), with one of these experiencing intrauterine fetal death before 12 week' gestation. Conclusion: This study demonstrates that a daily dose of cetrorelix 0.2 mg is able to prevent premature LH surge.
| Original language | English |
|---|---|
| Pages (from-to) | 289-292 |
| Number of pages | 4 |
| Journal | Journal of Assisted Reproduction and Genetics |
| Volume | 23 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Jun 2006 |
Fingerprint
Keywords
- Cetrorelix
- GnRH antagonist
- In vitro fertilization
- LH surge
ASJC Scopus subject areas
- Developmental Biology
- Genetics
- Obstetrics and Gynaecology
- Reproductive Medicine
Cite this
Is a lower dose of cetrorelix acetate effective for prevention of LH surge during controlled ovarian hyperstimulation? / Chen, Heng J.; Lin, Yu Hung; Hsieh, Bih Chwen; Seow, Kok M.; Hwang, Jiann-Loung; Tzeng, Chii Ruey.
In: Journal of Assisted Reproduction and Genetics, Vol. 23, No. 6, 06.2006, p. 289-292.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Is a lower dose of cetrorelix acetate effective for prevention of LH surge during controlled ovarian hyperstimulation?
AU - Chen, Heng J.
AU - Lin, Yu Hung
AU - Hsieh, Bih Chwen
AU - Seow, Kok M.
AU - Hwang, Jiann-Loung
AU - Tzeng, Chii Ruey
PY - 2006/6
Y1 - 2006/6
N2 - Purpose: This study was performed to evaluate whether a lower dose (0.2 mg) of cetrorelix would prevent premature LH surge in patients undergoing controlled ovarian hyperstimulation. Methods: Controlled ovarian hyperstimulation was carried out in 45 patients, starting on menstrual cycle day 3 with recombinant FSH (r-FSH), and a cetrorelix of 0.2 mg was administered from day 5 evening of ovarian stimulation until the day before hCG injection. Results: There was a statistically significant decrease in serum LH level one day after the first cetrorelix injection and on the day of hCG administration. Serum LH concentrations were maintained constantly low during the follicular phase with no premature LH surge occurring in any of the patients. Clinical pregnancy was achieved for 18 women (40%), with one of these experiencing intrauterine fetal death before 12 week' gestation. Conclusion: This study demonstrates that a daily dose of cetrorelix 0.2 mg is able to prevent premature LH surge.
AB - Purpose: This study was performed to evaluate whether a lower dose (0.2 mg) of cetrorelix would prevent premature LH surge in patients undergoing controlled ovarian hyperstimulation. Methods: Controlled ovarian hyperstimulation was carried out in 45 patients, starting on menstrual cycle day 3 with recombinant FSH (r-FSH), and a cetrorelix of 0.2 mg was administered from day 5 evening of ovarian stimulation until the day before hCG injection. Results: There was a statistically significant decrease in serum LH level one day after the first cetrorelix injection and on the day of hCG administration. Serum LH concentrations were maintained constantly low during the follicular phase with no premature LH surge occurring in any of the patients. Clinical pregnancy was achieved for 18 women (40%), with one of these experiencing intrauterine fetal death before 12 week' gestation. Conclusion: This study demonstrates that a daily dose of cetrorelix 0.2 mg is able to prevent premature LH surge.
KW - Cetrorelix
KW - GnRH antagonist
KW - In vitro fertilization
KW - LH surge
UR - http://www.scopus.com/inward/record.url?scp=33748780621&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748780621&partnerID=8YFLogxK
U2 - 10.1007/s10815-006-9054-0
DO - 10.1007/s10815-006-9054-0
M3 - Article
VL - 23
SP - 289
EP - 292
JO - Journal of Assisted Reproduction and Genetics
JF - Journal of Assisted Reproduction and Genetics
SN - 1058-0468
IS - 6
ER -